Access to Newer Antibiotics Remains Bottlenecked by Fragmented AMR Governance Across Asia
Access to newer antibiotics for antimicrobial resistant infections is being held back by more than pricing or procurement alone. A qualitative study spanning multiple Asian countries found a layered access problem shaped by divergent views of AMR urgency, short-term workarounds, thin infrastructure, and a lack of coordinated leadership across the actors expected to solve it.
The findings matter because resistant bacterial infections do not wait for policy alignment. When clinicians face pathogens that are no longer susceptible to older drugs, delays in obtaining a newer agent can force treatment choices that are less effective, more toxic, or both.
Divergent Priorities Split the Response Before Patients Reach the Ward
Between April 2024 and April 2025, investigators conducted semi-structured interviews with stakeholders from Cambodia, China, India, Indonesia, Japan, Malaysia, Singapore, Sri Lanka and Thailand. Forty of 79 invited participants took part, representing policymakers, regulators, healthcare professionals, pharmaceutical companies, global health actors, health technology assessors, and patient advocacy groups. The analysis used a seven-stage framework approach, which is well suited to drawing out recurring patterns across different stakeholder groups and health systems.
One of the clearest themes was misalignment in how AMR risk is understood across settings. Perceptions of urgency differed between higher-income and lower-income countries, and those differences shaped implementation. Where one group sees a pressing public health emergency, another may treat the problem as future-facing or secondary to more immediate system demands. In practical terms, that split weakens the political and operational momentum needed for coordinated access reforms.
A short paragraph captures the clinical consequence: fractured urgency produces fractured access.
The study describes how this gap feeds disjointed interventions and reliance on inefficient workaround access mechanisms. Those workarounds may keep a single patient treated in the moment, but they are not a durable access strategy. Without sustained policy attention, stewardship and infection prevention and control programs also lose continuity, allowing resistance pressure to persist while newer agents remain hard to obtain.
Weak Infrastructure and Thin Market-Shaping Capacity Limit Real-World Availability
Beyond mindset and governance, the interviews pointed to structural underinvestment. Clinical trial capacity, regulatory processes, infrastructure, and market-shaping mechanisms were all described as underdeveloped or insufficiently supported. Each of these components affects a different step in the pathway from drug development to bedside use.
Clinical trial capacity determines whether evidence can be generated locally and in a way that reflects regional resistance patterns. Regulatory systems determine how quickly products can be reviewed and authorized. Market-shaping tools influence whether manufacturers see enough predictable demand to sustain supply. When each step is fragile, access becomes erratic even if a product exists elsewhere in the region or globally.
The biological logic is straightforward. Resistant infections demand timely exposure to agents with activity against hard-to-treat pathogens, and delays in access can convert a treatable infection into a prolonged, resource-intensive illness. In that setting, access is not an administrative abstraction; it is a determinant of whether appropriate therapy can be started early enough to matter.
Siloed Responsibility Leaves No Single Actor Accountable
The interviews also exposed a governance gap. Responsibilities remained siloed across stakeholders, while global health actors were not able to close the accountability void on their own. This matters because access to antimicrobials sits at the intersection of procurement, regulation, stewardship, clinical practice, financing, and surveillance. When no single entity can coordinate those domains, reform efforts tend to stall at the handoff points.
Stakeholders described a system in which each actor can identify part of the problem but none can fully own the solution. Regulators can process approvals, but they cannot by themselves solve procurement instability. Industry can supply products, but it cannot harmonize policy or create stewardship frameworks. Health systems can define clinical need, but they cannot always influence regional manufacturing or pooled purchasing arrangements.
That fragmentation creates a familiar pattern: isolated success, collective inertia.
The study’s interpretation points toward a more integrated model. Equitable access to newer antibiotics depends on health system strengthening, coherent evidence generation, and partnerships that connect government, private sector, and global health actors. Regulatory harmonisation and pooled procurement were identified as concrete mechanisms that could reduce the immediate barriers now limiting access.
Why the Study Resonates Beyond the Participating Countries
Although the interviews came from nine Asian countries, the underlying problem is broader. Many health systems are trying to confront AMR while still operating with uneven regulatory capacity, variable stewardship programs, and limited leverage over pharmaceutical supply chains. Newer antibiotics sit at the center of that tension: they are most needed where resistance is most severe, yet they often face the steepest access barriers in precisely those settings.
Qualitative evidence has value here because it captures the governance and behavioral constraints that do not show up in a simple price list or formulary review. A medicine can be scientifically promising and still remain clinically inaccessible if the surrounding system cannot support evaluation, purchasing, distribution, and responsible use. The study makes clear that access failures are rarely caused by one bottleneck alone. They emerge from a chain of weak links, each reinforcing the next.
For clinicians, the practical implication is sobering. When a resistant infection is suspected, the availability of the right antibiotic may depend on decisions made far upstream in ministries, regulatory agencies, procurement offices, and international partnerships. For policymakers, the message is equally direct: improving access to newer antibiotics will require more than emergency exceptions or episodic donor support. It will require durable coordination, shared accountability, and investment in the systems that move evidence into practice.
The study does not quantify patient outcomes or measure the impact of any single reform strategy. Its strength lies elsewhere: in showing how access barriers accumulate across the policy chain, and in identifying where regional cooperation could start to loosen the bottleneck. The next challenge is not defining the problem more clearly. It is building the governance architecture that can support reliable access before another resistant infection narrows the treatment window.